Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Stem Cells

Stem Cells

12

Pipeline Programs↗

28

Active Trials↗

15

Companies Involved↗

Stem Cells is an emerging landscape with 12 programs across 15 companies. The most active players are Guangdong ProCapZoom Biosciences Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

22/100

Mech. Concentration

50/100

Completion Rate

72/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Guangdong ProCapZoom Biosciences Co., Ltd.

1 program

Pipeline

Programs by Phase

Preclinical2

Blood

University Hospital, Lille

Adipose-Derived Stem Cells

Xuzhou Medical University

Phase 14

Stem Cells Lenses

Guangdong ProCapZoom Biosciences Co., Ltd.

G-CSF

Arog Pharmaceuticals, Inc.

Hexell-2020

Hexun Biosciences Co., LTD.

Allorx

The Foundation for Orthopaedics and Regenerative Medicine

Phase 26

Myelostim

IRCCS San Raffaele

Mozobil

National Institute of Allergy and Infectious Diseases (NIAID)

Ibuprofen

Kenvue Brands

Plerixafor

Genzyme, a Sanofi Company

Hmsc

Stemedica Cell Technologies, Inc.

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

67%

Small molecule

6 of 9 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.

Analysis

Trial Status

182

clinical trials

Unknown status64 · 35%

Completed62 · 34%

Recruiting18 · 10%

Withdrawn14 · 8%

Terminated9 · 5%

Active, not recruiting5 · 3%

Other10 · 5%

Clinical Trials

Trial Activity

182 trials

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06414889·4 enrolled

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

Recruiting·—·Phase 1·NCT05343572·90 enrolled

Efficacy of Preconditioned Adipose-Derived Stem Cells in Fat Grafting

Recruiting·UUniversity of the Punjab·Phase 1·NCT05610878·24 enrolled

Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD

Recruiting·IIRCCS San Raffaele·Phase 2·NCT03055247·3 enrolled

The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-LDP) for Lumbar Discogenic Pain

Recruiting·SSclnow Biotechnology Co., Ltd.·Phase 1·NCT04104412·242 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for PCOS

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT06143527·20 enrolled

Effect of Different Frequencies of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients with ESLD

Recruiting·GGeneral Hospital of Shenyang Military Region·N/A·NCT06242405·92 enrolled

Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells

Recruiting·TThe Methodist Hospital Research Institute·Phase 1·NCT06798623·15 enrolled

Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.

Recruiting·—·Phase 2·NCT06781333·8 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147701·20 enrolled

Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07212335·15 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Pulmonary Diseases

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147688·20 enrolled

Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy in Group E COPD Patients

Recruiting·RRSUP Persahabatan·Phase 2·NCT07441226·20 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for SCI

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05152290·20 enrolled

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for OA

Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147675·92 enrolled

Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)